https://www.usheadlinesnews.com/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b-3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19/